Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Maze Therapeutics, Inc.

NASDAQ: MAZE · Life Sciences · 8 alerts · CIK 1842295

Share price
$33.90Close, Nov 16
Market cap
$1.85B
Shares outstanding
54.68MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Maze Therapeutics, Inc. filings on SEC EDGAR ↗

4:15 PM ET 10-Q
Financial Results

Maze Therapeutics Q3 2026 Results: Net Loss of $48M, Loss Widens

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on its Compass platform and lead therapeutic candidates MZE829 and MZE782. As of November 4, 2026, the company had 54,683,345 shares of common stock outstanding and continues to report significant operating losses with no product revenue generated to date.

Key figure
Net loss $48M
4:10 PM ET 8-K
Financial Results

Maze Therapeutics Financial Results

Maze Therapeutics reported third quarter 2026 financial results, ending the period with $477 million in cash and a projected runway into 2029. The company highlighted the completion of enrollment for its Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease, with data expected in early 2027. Net loss for the quarter was $38.4 million, driven by increased R&D expenses related to its clinical-stage pipeline.

Term
Q3 2026

“Completing enrollment in HORIZON with more than 50 patients across three cohorts marks an important milestone for MZE829 and exceeded our target enrollment of 10-15 patients per cohort. HORIZON gives us the opportunity to generate a robust dataset across three distinct AMKD patient populations, including patients with and without diabetes and those with FSGS, and provide a comprehensive view of MZE829’s potential as a best-in-class therapy for a broad AMKD population, supported by its differentiated dual mechanism of action.”

Jason Coloma, Ph.D., chief executive officer of Maze

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.